All In Biotech

Drug Trial Radar · NCT04102150

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

A Phase 2, Multicenter, Open-label, Single-arm Study of Valemetostat Tosylate (DS-3201b) in Patients With Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Nov 21, 2019

Primary completion

Apr 24, 2021

Study completion Oct 27, 2024

Sponsor

Lead sponsor
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Sep 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).

Conditions

  • Adult T-cell Leukemia/Lymphoma

Interventions

  • Valemetostat TosylateDrug

    Once a day, 200 mg, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR) assessed by central evaluation organizationTime frame: Through the end of the study (within approximately 5 years)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Kagoshima University Hospital

    Kagoshima, Japan

  • Nagasaki University Hospital

    Nagasaki, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • Ehime University Hospital

    Tōon-shi, Ehime, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Imamura General Hospital

    Kagoshima, Kagoshima-ken, Japan

  • Kochi Medical School Hospital

    Nankoku-shi, Kochi, Japan

  • Kumamoto University Hospital

    Kumamoto, Kumamoto, Japan

  • National University Corporation Tohoku University Tohoku University Hospital

    Sendai, Miyagi, Japan

  • University of Miyazaki Hospital

    Miyazaki, Miyazaki, Japan

  • Local Incorporated Administrative Agency Sasebo City General Hospital

    Sasebo-shi, Nagasaki, Japan

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan

  • University of the Ryukyus Hospital

    Nakagami-gun, Okinawa, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Kindai University Hospital

    Osakasayama-shi, Osaka, Japan

  • Osaka University Hospital

    Suita-shi, Osaka, Japan

  • Saga University Hospital

    Saga, Saga-ken, Japan

  • Saitama Medical University International Medical Center

    Hidaka-shi, Saitama, Japan

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

  • IMSUT Hospital, The Institute of Medical Science, The University of Tokyo

    Minato-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.